DNA-Guided depression treatment tested in morocco

NCT ID NCT07480486

Not yet recruiting Knowledge-focused Sponsor: Mohammed V University in Rabat Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether using a person's genetic information can help doctors choose the best antidepressant for major depressive disorder. 570 adults in Morocco will be randomly assigned to either genetic-guided treatment or standard care. Researchers will track depression symptoms over 12 weeks to see if the genetic approach leads to higher remission rates.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pharmacogenetic testing
What this could lead to: If successful, this could show that genetic testing helps doctors pick the right antidepressant faster, improving depression treatment.
What could go wrong: This is an early-stage study in one country, and results may not apply elsewhere. Genetic testing might not improve outcomes over standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEPRESSION - MAJOR DEPRESSIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Depression dysthymic disorder major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEPRESSION - MAJOR DEPRESSIVE DISORDER

Contacts and locations

Locations

Ar-Razi Psychiatric Hospital, Ibn Sina University Hospital

Rabat, Rabat-Salé-Kénitra, 40000, Morocco

More trials for these conditions

Other studies related to the condition(s) this trial covers.